Company / Operating Cash Flow
Xenon Pharmaceuticals Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$279.1M
FY2025
5-year range
-$279.1M / -$69.5M
FY2021-FY2025
Trend
-53.9%
vs FY2024
Sector context
#190 of 216
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s operating cash flow of -$279M is lower than 88% of companies in the Health Care sector (FY2025). Operating Cash Flow has declined for 6 consecutive years, from -$5M in FY2019 to -$279M in FY2025.
Based on SEC 10-K filings.
-$279M in FY2025.
Declined from -$151M to -$279M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 216This company -$279.1M Sector average $658.7M
▼
-142.4% below sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s operating cash flow has declined for 6 consecutive years.
- In FY2025, operating cash flow decreased 53.9% year-over-year.
- Ranks #190 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$279.1M | -53.9% |
| FY2024 | -$181.4M | -20.0% |
| FY2023 | -$151.1M | -49.6% |
| FY2022 | -$101.0M | -45.4% |
| FY2021 | -$69.5M | -44.4% |
| FY2020 | -$48.1M | -920.9% |
| FY2019 | -$4.7M | +86.4% |
| FY2018 | -$34.7M | -91.8% |
| FY2017 | -$18.1M | +7.5% |
| FY2016 | -$19.6M | -8.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026